10975077 2024-11-01 2025-10-31 10975077 2024-11-01 2025-10-31 1 10975077 2024-11-01 2025-10-31 2 10975077 2024-11-01 2025-10-31 1 10975077 2024-11-01 2025-10-31 2 10975077 2024-11-01 2025-10-31 3 10975077 2024-11-01 2025-10-31 1 10975077 2023-11-01 2024-10-31 10975077 2025-10-31 10975077 2024-10-31 10975077 2024-10-31 fsa:ContributedCapitalMember 10975077 2024-10-31 fsa:RetainedEarningsMember 10975077 2024-10-31 fsa:ProposedDividendRecognisedInEquityMember 10975077 2024-11-01 2025-10-31 fsa:ContributedCapitalMember 10975077 2024-11-01 2025-10-31 fsa:RetainedEarningsMember 10975077 2024-11-01 2025-10-31 fsa:ProposedDividendRecognisedInEquityMember 10975077 2025-10-31 fsa:ContributedCapitalMember 10975077 2025-10-31 fsa:RetainedEarningsMember 10975077 2025-10-31 fsa:ProposedDividendRecognisedInEquityMember iso4217:DKK xbrli:pure Chris Gray The Supervisory Board and the Executive Board have today discussed and approved the annual report for ORIGIO A/S for the financial year 1 November 2024 - 31 October 2025.The annual report has been prepared in accordance with the Danish Financial Statements Act.In our opinion, the financial statements give a true and fair view of the Company's assets, liabilities and financial position at 31 October 2025 and of the results of the Company's operations for the financial year 1 November 2024 - 31 October 2025.Further, in our opinion, the Management's review gives a fair review of the development in the Company's activities and financial matters, of the results for the year and of the Company's financial position.We recommend that the annual report be approved at the annual general meeting. Ballerup, Kim M Shaffer CEO Nigel Anton Penfold Executive Officer Holly Sheffield Chairman Agostino Ricupati Brian George Andrews To the shareholder of ORIGIO A/S OpinionWe have audited the financial statements of ORIGIO A/S for the financial year 1 November 2024 - 31 October 2025, comprising income statement, balance sheet, statement of changes in equity and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.In our opinion, the financial statements give a true and fair view of the Company's assets, liabilities and financial position at 31 October 2025 and of the results of the Company's operations for the financial year 1 November 2024 - 31 October 2025 in accordance with the Danish Financial Statements Act. Basis for OpinionWe conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report.We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code.We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. Management's responsibility for the financial statementsManagement is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control that Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. Auditor's responsibilities for the audit of the financial statementsOur objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements in Denmark will always detect a material misstatement when it exists. Misstatements may arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of financial statement users made on the basis of these financial statements.As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also●identify and assess the risks of material misstatement of the company financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.●obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.●evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.●conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.●evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.●plan and perform the audit of the financial statements to obtain sufficient appropriate audit evidence regarding the consolidated financial information of the entities or business units as a basis for forming an opinion on the financial statements. We are responsible for the direction, supervision and review of the audit work performed. We remain solely responsible for our audit opinion.We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. Statement on the Management's reviewManagement is responsible for the Management's review.Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Management's review. Copenhagen, KPMGStatsautoriseret Revisionspartnerselskab 25578198 Ilhan Dogan State Authorised Public Accountant mne47842 ORIGIO A/S Lautrupvang 2, 1. th 2750 Ballerup 80 82 01 31 sales@coopersurgical.com 10975077 Ballerup Dampfærgevej 28 DK 2100 København Ø Financial highlightsDKK'0002024/25 2023/24 2022/23 2021/22 2020/21Revenue760,810 863,647 932,011 929,787 909,643Gross profit157,449 159,167 153,999 150,748 185,823Profit before financial income and expenses 32,868 28,390 28,402 37,169 60,982Profit/loss from financial income and expenses - 23,563 - 8,128 9,892 - 24,761 - 9,607Profit/loss for the year4,884 13,026 29,279 - 111,707 36,973Total assets443,349 445,927 527,516 514,580 526,224Investments in property, plant and equipment 785 7,697 48 0 849Equity171,727 186,843 316,817 287,538 429,245Return on equity2.7% 5.2% 9.7% - 31.2% 7.9%Solvency ratio38.7% 41.9% 60.1% 55.9% 81.6%Average number of full-time employees 107 111 121 129 157The financial ratios have been calculated as follows:Return on equity Profit/loss after tax x 100 / Average equityEquity at year end x 100 / Total equity and liabilities at Solvency ratioyear endUncertainty regarding recognition and measurementDetermining the carrying amounts of certain assets and liabilities requires an estimate of how future events will affect the value of these assets and liabilities at the balance sheet date. Estimates that are material to the financial statements are made regarding measurement of equity investments in group companies and uncertain tax positions.The estimates are based on assumptions that management believes are reasonable but which are inherently uncertain and unpredictable. The assumptions may be incomplete or inaccurate, and unexpected events or circumstances may occur. The Company is also subject to risks and uncertainties that may cause actual results to differ from these estimates.The impairment assessment of investments in group companies are based on expectations of future cash flows of the individual companies. The assessment requires the establishment of assumptions and estimates of future cash flows and discount rate (WACC).The assessment of uncertain tax positions is based on determine whether it is probable that a benefit may be recognized and measure the amount of the benefit based on the probability of different outcomes.Moreover, reference is made to note 2, in which the matter is described in further detail.Development in activities and financial positionProfit for the year (including comparison with outlook previously announced)The Company's income statement for the period 1 November 2024 - 31 October 2025 shows a profit for the year after tax of DKK 4,884 thousand as against a profit after tax of DKK 13,026 thousand in the period 1 November 2023 - 31 October 2024. Equity in the Company's balance sheet at 31 October 2025 stood at DKK 171,727 thousand as against DKK 186,843 thousand at 31 October 2024.Management considers the results for the year satisfactory due to the operating profit being t.DKK 32.868 against an expected operating profit of t.DKK 32,000.Origio A/S has received a tax claim from the Danish Tax Authorities relating to the sale of IP rights in 2018 to group companies. The amount claimed is DKK 115.115 thousand plus accumulated interest. The interest expense for the period 1 November 2024 - 31 October 2025, which has been expensed in this financial report, is DKK 21.217 thousand. As at 31 October 2025, total accumulated interest of DKK 76.924 thousand has been expensed resulting in a total claim of DKK 192,040. The claim is currently being negotiated as Origio A/S does not agree with the valuation used by the tax authorities. The final outcome of the claim can therefore be significantly different than the provided amount. As a consequence, Origio A/S has received approval to delay payment until 31st March 2027.Special risksThe Company's activities and business model involve a number of general and specific commercial and financial risks, which may have negative impacts on its future growth.Business risksManagement continues to focus on the most important operational risks and to evaluate the current mitigation plans. Regulations on ART products continue to intensify, and the company expects these requirements to further increase in the future. The company has established knowledge and competencies in the regulatory area and is prepared to meet the increased regulatory demand.Financial risksDevelopments in the company's results and equity are not significantly impacted by financial risks. Whilst a proportion of the revenue comes from markets outside Denmark, the majority of revenue is invoiced in DKK and EUR limiting the exposure of exchange rate risks. The company does not engage in speculative financial transactions.OutlookManagement expects an operating profit for 2025/26 of DKK 32 million. This is of similar level as realised for 2024/25.BranchesOrigio A/S has branches in Dubai and the Czech Republic.Operating reviewEvents after the balance sheet dateThere are not identified any subsequent events that could have a material impact on the Company's financial position. Principal activitiesORIGIO has been part of the CooperSurgical Companies since 2012. CooperSurgical Fertility Solutions is the global leader in IVF (In Vitro Fertilisering) and reproductive genetics, providing innovative products and services for every step in the ART journey (Assisted Reproductive Technology). Our company vision is a world with healthy women, babies and families.ORIGIO A/S was established in 1987 and has been a global leader in delivering innovative ART solutions. Combining the scientific knowledge with the CooperSurgical fertility companies ORIGIO, Research Instrument, Safe Obstetrics Systems and Invitro offer a broad range of trusted systems of consumables, equipment, and technologies for a complete IVF process.In 2016 Reprogenetics, Recombine and Genesis Genetics joined the CooperSurgical family, and represented the pioneers and global leaders of comprehensive reproductive genetic testing. As CooperGenomicsSM, they are the premier provider of genetic testing for every step of the family planning journey.Our combined product range includes pipettes, media and andrology products, and dedicated ART equipment, as well as state-of-the art electronic witnessing system.Our broad portfolio of products and services are being developed jointly in partnerships with experts and clinics across the globe to improve the ART solutions.Our industry-leading ART development program includes 7 Centers of Excellence around the world as well as collaboration with our external partners' training facilities, such as the Centre of Reproductive Medicine at the Vrije Universiteit Brussel in Brussels. We offer a wide range of courses and workshops for embryologists, gynecologists, lab managers and R&D scientists at every level of experience, with hands-on expert training in breakthrough technologies and next-generation techniques. Our team of experienced embryologists also assists customers with the establishment of clinics (tum-key projects), laboratory design, and clinic audits to optimize lab performance. In addition, they give lectures, run seminars and workshops, and support the research and development of new products.ORIGIO will continue its focus to further grow and strengthening it's strong position in offering best in class products, driving and evolving innovation in line with customer needs. The collaboration within the CooperSurgical Companies and trusted partnerships open doors to extensive possibilities for the future. Statement on corporate social responsibilityWe conduct all our activities with deep respect for all our stakeholders and have a constant focus on Corporate Social Responsibility. Being part of The Cooper Companies, publicly traded on the NASDAQ in which the Company is included as a subsidiary, we conduct all our activities in accordance with the procedures and policies stated in the global ESG report. The ESG report is published once a year and covers the calendar year - latest report can be found on the following website: https://www.coopercos.com/esg/The main activity for Origio A/S is selling and distributing products and services within assisted reproductive technology (ART). CooperSurgical fertility solutions is the global leader in IVF (In Vitro Fertilization) and reproductive genetics. Origio A/S is selling products, manufactured by group companies, in Scandinavia and the Baltics in our own name, and globally via distributors.Climate targets and environmental mattersOrigio A/S has an office consisting of different departments such as sales, marketing and finance, which has no significant environmental impact.Social and employee staff mattersThe most material risk related to employees is the risk of injuries at work or work-related illnesses. Origio A/S is committed to providing safe and healthy working conditions for our employees, customers, and business partners in order to achieve zero injuries and near misses and work-related illness (both physical and mental).Our Workers Council have frequent meetings with our employees to ensure they feel heard and respected.The ongoing work will continue unchanged for the coming years.We have had no known incidents during the reporting period 2024/2025.Human rightsFor Origio A/S, the most material risk of violating human rights will exist within our supply chain. As part of a globally group of companies, we conduct our business in a way that we respect the human rights and dignity off all people in our organization.Origio A/S has zero tolerance for any human rights violations. We are therefore committed to reporting any suspicion or evidence of human rights abuses in our organization or in the operations of our suppliers or other businesses.The company performs quarterly training for all employees who have a company email address to ensure everyone has a clear understanding of their obligations in this area.The ongoing work on human rights will continue unchanged for the coming years.We have not identified any breaches of our policy related to human rights during the reporting period 2024/2025.Anti-CorruptionThe most material risk in this area relate to the risk of unethical behavior amongst our customers and business partners. Origio A/S is therefore committed to ensuring that the company, its subsidiaries, affiliates, management, employees, representatives, and any business partners fully comply with all anticorruption and anti-bribery laws what are applicable to them.To make sure we are complying with relevant laws, the company performs yearly training with all employees, especially related to interactions with health care professionals and government officials, including rules for gifts, entertainments, and hospitality.The ongoing work in this respect will continue unchanged for the coming years.We have not identified any breaches of our policy related to anti-corruption and bribery during the reporting period 2024/2025.Climate impactAs described in our business model Origio A/S has very limited impact on the environment as the principal activity is selling the products already produced by our parent company. We therefore have not identified any material risks related to either our environmental or climate impact. As our business model does not cover any material risks related to environment or climate, we see no reason to formulate a formal policy related to the matter as of now. Statement on data ethicsOrigio A/S is part of The Cooper Companies group. The Cooper Companies conducts its business in accordance with our core values and our global Code of Conduct, which defines the ethical principles guiding how we work with our people, business partners, and the communities in which we operate. Our approach is grounded in Integrity, Excellence, Doing What’s Right, Respect, and Responsibility to Our Communities.We are committed to the ethical use of data and to safeguarding the information entrusted to us. This means using data responsibly, lawfully, and fairly, with clear purpose, appropriate transparency, and respect for individual rights. Throughout implemented privacy-by-design processes, we ensure that data is collected, accessed, and processed ethically. The Cooper Companies is committed to the ethical use of data, including when deploying analytics and automated or AI‑enabled tools. We seek to ensure that data‑driven activities are fair, appropriate, and aligned with our values and Code of Conduct. This includes considering potential bias in data sets, ensuring proportional and explainable use of automated decision‑making, maintaining appropriate human oversight, and using data only for defined and legitimate purposes. Ethical considerations are embedded into our governance, risk assessment, and privacy‑by‑design processes, alongside compliance with applicable laws, regulations, and industry standards 760810000 863647000 484114000 575173000 119247000 129307000 157449000 159167000 122748000 128211000 1833000 2566000 32868000 28390000 0 6361000 1725000 5927000 25288000 20416000 9305000 20262000 4421000 7236000 4884000 13026000 13000 470000 3528000 4552000 3028000 2596000 6556000 7148000 187769000 183427000 194338000 191045000 129108000 132029000 82423000 71176000 1711000 1772000 17263000 16763000 6160000 9004000 236665000 230744000 12346000 24138000 249011000 254882000 443349000 445927000 162703000 162703000 9024000 4140000 0 20000000 171727000 186843000 3727000 4920000 36983000 41890000 229155000 210878000 1757000 1396000 271622000 259084000 271622000 259084000 443349000 445927000 162703000 4140000 20000000 186843000 0 0 20000000 20000000 0 4884000 0 4884000 162703000 9024000 0 171727000 true Omission of presentation of consolidated financial statementsPursuant to section 112(1) of the Danish Financial Statements Act, no consolidated financial statements have been prepared. The financial statements of ORIGIO A/S and group entities are included in the consolidated financial statements of The Cooper Companies, Inc., United States. Omission of cash flow statementPursuant to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The Company's cash flows are included in the cash flow statement in the consolidated financial statements of The Cooper Companies, Inc., which can be found on https://investor.coopercos.com/financial-information/sec-filings. Recognition and measurementAssets are recognised in the balance sheet when it is probable as a result of a prior event that future economic benefits will flow to the Company, and the asset can be measured reliably.Liabilities are recognized in the balance sheet when the Company has a legal or constructive obligation as a result of a prior event, and it is probable that the future economic benefits will flow out of the Company, and the value of the liability can be measured reliably. On initial recognition, assets and liabilities are measured at cost. Measurement subsequent to initial recognition is effected as described below for each financial statement item.Income is recognized in the income statement when earned, whereas costs are recognized by the amounts attributable to this financial year.Foreign currency translationTransactions in foreign currency are translated by using the exchange rate prevailing at the date of the transaction. Differences in the rate of exchange arising between the rate at the date of transaction and the rate at the date of payment are recognised in the profit and loss account as an item under financial income and expenses.Debtors, creditors, and other monetary items in foreign currency are translated by using the closing rate. The difference between the closing rate and the rate at the time of the occurrence or the recognition in the latest annual accounts of the amount owed or the liability is recognised in the profit and loss account under financial income and expenses.Fixed assets and other non-monetary assets acquired in foreign currency and which are not considered to be investment assets purchased in foreign currencies are measured at the exchange rate on the transaction date.Income statementRevenueRevenue is recognised in the income statement if delivery and passing of risk to the buyer have taken place before the end of the year and if the income can be determined reliably and inflow is anticipated. Revenue is measured at the fair value of the consideration promised exclusive of VAT and taxes and less any discounts relating directly to sales.Cost of salesCost of sales comprises costs incurred to generate revenue for the year. This item also comprises direct costs for goods for resale and changes to inventory of goods for resale.Other external costsOther external costs comprise costs for distribution, sales, advertisement, administration, premises, loss on debtors, and operational leasing costs.Staff costsStaff costs include salaries and wages, including holiday allowances, pensions, and other social security costs, etc., for staff members.Financial income and expensesNet financials comprise interest income and expenses, dividends and gain/loss of sale of investments and transactions in foreign currencies as well as interest surcharges and refunds under the on-account tax scheme, etc. Financial income and expenses are recognised in the profit and loss account with the amounts that concerns the financial year.Dividend from equity investments in subsidiaries is recognised in the financial year in which the dividend is declared.Tax on profit for the yearThe tax for the year comprises the current tax for the year and the changes in deferred tax, and it is recognised in the profit and loss account with the share referring to the results for the year and directly in the equity with the share referring to entries directly on the equity.The Company is subject to Danish rules on compulsory joint taxation of Danish group enterprises. The company acts as an administration company in relation to the joint taxation. This means that the total Danish tax payable by the Danish consolidated companies is paid to the tax authorities by the company.The current Danish corporate tax is allocated among the jointly taxed companies in proportion to their respective taxable income (full allocation with reimbursement of tax losses).Balance sheetIntangible assetsPatents, licences and trademarksPatents, licenses, trademarks and customer lists are measured at costs less accumulated amortization and impairment losses. Patents, trademarks and customer lists are amortized on a straight-line basis over the remaining life, and licenses are amortized over the contract period, however not exceeding 5 years.Gains and losses on the disposal of intangible assets are determined as the difference between the selling price less selling costs and the carrying amount at the date of disposal.Property, plant and equipmentFittings, tools and equipment and leashold improvements are measured at cost less accumulated depreciation and impairment losses.The basis of depreciation is cost with deduction of any expected residual value after the end of the useful life of the asset. The depreciation period and the residual value are determined at the acquisition date and reassessed annually. If the residual value exceeds the book value, the depreciation discontinues.If the deprecition period or the residual value is changed, the effect on depreciation will in the future be recognised as a change in the accounting estimates.The cost comprises the acquisition cost and costs directly attached to the acquisition until the time when the asset is ready for use. The cost of a total asset is divided into separate components. These components are depreciated separately, the useful lives of each individual components differing. Depreciation takes place on a straight line basis and based on an evaluation of the expected useful life:Fixtures and fittings, tools and equipment 3-10 yearsLeasehold improvements 7 yearsMinor assets with an expected useful life of less than 1 year are recognised as costs in the income statement in the year of acquisition.Gains and loss deriving from the sales of tangible fixed assets is measured as the difference between the sales price reduced by the selling costs and the book value at the time of the sale. Gains and losses are recognised in the income statement as other operating income or other operating costs.LeasesAll leases are accounted for as operating leases. Payments relating to operating leases and other leases are recognised in the income statement over the term of the lease. The Company's total obligation relating to operating leases and other leases is disclosed as contractual obligations and contingencies, etc.Financial assetsEquity investments in group entities are measured at cost. In case of indication of impairment, an impairment test is conducted. When the cost exceeds the recoverable amount, write-down is made to this lower value.Impairment of fixed assetsThe book values of both intangible and tangible fixed assets as well as equity investments in group entities are subject to annual impairment tests in order to disclose any indications of impairment beyond those expressed by amortisation and depreciation respectively.If indications of impairment are disclosed, impairment tests are carried out for each individual asset or group of assets respectively. Writedown takes place to the recoverable amount, if this value is lower than the book value.The recoverable value is equal to the value of the net selling price or the value in use, whichever is higher. The value in use is determined as the present value of the expected net cash flow deriving the use of the asset or the group of assets.Previously recognised writedown is reversed when the condition for the writedown no longer exist. Writedown relating to goodwill is not reversed.ReceivablesReceivables are measured at amortised cost. Write-down is made for bad debt losses where there is an objective indication that a receivable has been impaired. If there is an objective indicaton that an individual receivable has been impaired, write-down is made on an individual basis. Write-downs are calculated as the difference between the carrying amount of receivables and the present value of forecast cash flows, including the realisable value of any collateral received. The effective interest rate for the individual receivale or portfolio is used as discount rate.Corporation tax and deferred taxCurrent tax payable and receivable is recognised in the balance sheet as tax computed on the taxable income for the year, adjusted for tax on the taxable income of prior years and for tax paid on account.Deferred tax is measured using the balance sheet liability method on all temporary differences between the carrying amount and the tax value of assets and liabilities measured on the planned use of the asset or settlement of the liability, respectively. However, deferred tax is not recognised on temporary differences relating to office buildings non-deductible for tax purposes and other items where temporary differences arise at the date of acquisition without affecting either profit/loss or taxable income.Deferred tax assets, including the tax value of tax loss carryforwards, are recognised at the expected value of their utilisation within the foreseeable future; either as a set-off against tax in future income or as a set-off against deferred tax liabilities in the same legal tax entity. Any deferred net assets are measured at net realisable value.Deferred tax is measured in accordance with the tax rules and at the tax rates applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Changes in deferred tax as a result of changes in tax rates are recognised in the income statement or equity, respectively.PrepaymentsPrepayments recognised under assets comprise incurred costs concerning subsequent financial years.Cash at bank and in handCash and cash equivalents comprise cash at bank.EquityDividendsDividend expected to be distributed for the year is recognised as a separate item under equity. Proposed dividend is recognised as a liability at the time of approval by the general meeting (the time of declaration).LiabilitiesOther liabilities are measured at amortised cost which usually corresponds to the nominal value.Deferred incomeDeferred income comprises payments received regarding income in subsequent years. Uncertainty regarding recognition and measurementDetermining the carrying amounts of certain assets and liabilities requires an estimate of how future events will affect the value of these assets and liabilities at the balance sheet date. Estimates that are material to the financial statements are made regarding measurement of equity investments in group companies and uncertain tax positions.The estimates are based on assumptions that management believes are reasonable but which are inherently uncertain and unpredictable. The assumptions may be incomplete or inaccurate, and unexpected events or circumstances may occur. The Company is also subject to risks and uncertainties that may cause actual results to differ from these estimates.The impairment assessment of investments in group companies are based on expectations of future cash flows of the individual companies. The assessment requires the establishment of assumptions and estimates of future cash flows and discount rate (WACC). Reference is made to the investment note 12.The assessment of uncertain tax positions is based on determine whether it is probable that a benefit may be recognized and measure the amount of the benefit based on the probability of different outcomes. Segment informationOrigio A/S has activities in the segment for the promotion and sale of products within the women's healthcare industry. With reference to the provisions of section 96 of the Danish Financial Statements Act, the Executive Board has omitted information about the distribution of net sales on geographic markets, as the statements may cause significant damage to the company.Currency and interest rate risks and the use of derivative financial instrumentsThe Company is not exposed for any material currency or interest risks. The Majority of the business transactions and loan agreements are made in DKK or EUR. The Company does not have any material interest. Fees to auditors appointed at the annual general meetingDKK'0002024/25 2023/24Total fee to KPMG 665 645Statutory audit services 629 610Tax services 0 0Other services 36 35665 645 Staff costsDKK'0002024/25 2023/24Wages and salaries 114,877 120,424Pensions 6,555 6,977Other social security costs 1,316 810122,748 128,211 107 111 Pursuant to section 98b of the Danish Financial Statements Act, the remuneration of the executive board is not disclosed. The Supervisory Board members as well as the Executive Board members do not receive remuneration from Origio A/S. Financial incomeDKK'0002024/25 2023/24Interest income from group entities 0 3,087Other financial income 1,725 2,8401,725 5,927 Financial expensesDKK'0002024/25 2023/24Other interest expenses 127 57Exchange losses 5,575 3,383Percentage surcharge, corporation tax 19,586 16,97625,288 20,416 Tax on profit for the yearDKK'0002024/25 2023/24Current tax for the year 6,249 6,632Deferred tax adjustment for the year 92 887Refund in joint taxation arrangement 0 - 1,053Adjustment of tax concerning previous years - 1,889 - 945Adjustment of deferred tax concerning previous years - 31 1,7154,421 7,236 0 48000000 0 20000000 4884000 -54974000 Intangible assetsPatents, licences and DKK'000trademarksCost at 1 November 2024 19,303Cost at 31 October 202519,303Amortisation and impairment losses at 1 November 2024 - 18,833Amortisation - 457Amortisation and impairment losses at 31 October 2025- 19,290Carrying amount at 31 October 2025 13 Property, plant and equipmentFixtures and fittings, tools Leasehold DKK'000and equipmentimprovements TotalCost at 1 November 2024 7,850 2,833 10,683Additions 445 340 785Transferred - 640 640 0Cost at 31 October 20257,655 3,813 11,468Depreciation and impairment losses at 1 November 2024 - 3,300 - 237 -3,537Depreciation for the year - 827 - 548 -1,375Depreciation and impairment losses at 31 October 2025- 4,127 - 785 - 4,912Carrying amount at 31 October 2025 3,528 3,028 6,556 Financial assetsEquity investments in DKK'000group entitiesCost at 1 November 2024 248,389Additions 4,342Cost at 31 October 2025252,731Revaluations at 1 November 2024 - 64,962Revaluations at 31 October 2025- 64,962Carrying amount at 31 October 2025 187,769Financial assetsRegistered Profit/loss for Name/legal formoffice Equity interest Equitythe yearDKK'000 DKK'000Subsidiaries:Origio Australia Pty. Ltd.Australia 100.00% 1,300,457 1,263,038Origio Benelux B.V.The Netherlands 100.00% 14,685 1,112Origio France S.a.r.l.France 100.00% 15,944 2,099Origio GmbHGermany 100.00% 12,369 2,260Origio Italia S.R.L.Italy 100.00% 18,756 - 245Origio LLCRussia 100.00% 77,427 26,515Origio Cooper LLCRussia 100.00% 46,775 13,134Origio Ltd.United Kingdom 100.00% 28,020 4,302Origio India Pty Ltd.India 100.00% 67,916 5,025Origio Medicult España S.L.Spain 100.00% 25,388 1,672Origio Japan K.K.Japan 100.00% 17,975 2,470Aktieselskab af 20. november 2003Ballerup 100.00%170 01,625,882 1,321,382The impairment assessment of investments in group companies is based on expectations of future cash flows of the individual companies. The assessment requires the establishment and estimates of future cash flows and discount rate (WACC).The cash-flow is based on five-year financial projections (2026-2030), derived from managements approved budgets and expectations regarding future market developments. Beyond the explicit forecast period, a terminal value has been calculated using a long-term growth rate in line with inflation.The WACC applied in the impairment tests is based on a market participant perspective and reflects the group’s capital structure and risk profile. The WACC has been determined using peer group analysis and the CAPM, incorporating relevant inputs such as risk-free rate, market risk premium and capital structure. The used WACC is 8,5%.The impairment tests show that the recoverable amounts exceed the carrying values of the investments. Deferred tax assetsDKK'0002024/25 2023/24Deferred tax at 1 November 1,772 4,375Deferred tax adjustment for the year in the income statement -61 -2,603Deferred tax at 31 October1,711 1,772 PrepaymentsDKK'00031/10 2025 31/10 2024Vendor prepayments 65 902Prepaid registration costs 3,884 5,868Other prepayments 2,211 2,2346,160 9,004 Deferred incomeDeferred income comprise shipments where our revenue criteria are not met and prepayments from customers that have been received. Contractual obligations, contingencies, etc.Contingent liabilities, including guarantee commitmentsThe Company acts as administration company for the group of companies subject to the Danish scheme of joint taxation and is unlimitedly, jointly, and severally liable, along with the other jointly taxed companies, to pay the total corporation tax.The Company is unlimited jointly and severally liable with the other jointly taxed companies for any obligation to withhold tax on interest, royalties and dividends.The liability relating to obligations in connection with withholding tax on dividends, interest, and royalties represents an estimated maximum of DKK 0 thousand.Any subsequent adjustments of corporate taxes or withholding taxes, etc., may cause changes in the Company's liabilities. Other commitments, including lease obligationsThe Company has entered into operating leases at the following amounts:DKK'00031/10 2025 31/10 2024Short term:1,820 1,820Long term:5,157 7,1286,977 8,948 Related partiesORIGIO A/S is part of the consolidated financial statements of The Cooper Companies, 6101 Bollinger Canyon Road, San Ramon, California, United States, which is the smallest and largest group, in which the Company is included as a subsidiary.The consolidated financial statements of The Cooper Companies can be found on the following website: https://investor.coopercos.com/financial-information/sec-filingsRelated party transactionsDKK'0002024/25 2023/24Revenue from other related parties 56 46,363Revenue from subsidiaries -588 31,273Management fee income from other related parties 146,625 177,209Interest income from other related parties 0 3,087Dividend income from subsidiaries 0 6,361Purchase from other related parties 492,354 587,681Management fee expenses from other related parties 55,568 52,100Other expenses from other related parties 10,867 6,832Other expenses from subsidiaries 0 514Account receivables from other related parties 82,422 71,177Account payables other related parties 34,407 36,991Account payables subsidiaries 3,493 4,899 Annual report Auditor's report on audited financial statements ParsePort XBRL Converter 2024-11-01 2025-10-31 2023-11-01 2024-10-31 2026-05-13 Reporting class C, large enterprise 1987-07-01 2026-05-13 40119590 TK Consult ApS Hedekæret 50, 1. tv 2640 Hedehusene Opinion Basis for Opinion 2026-05-13